Ionis Pharmaceuticals Finalizes Patient Enrollment for Angelman Syndrome Treatment Trial

Ionis Pharmaceuticals has successfully completed patient enrollment for the pivotal Phase 3 REVEAL study, which is evaluating obudanersen as a potential treatment for Angelman syndrome. This investigational RNA-targeted medicine has enrolled 136 participants aged 2 to 18 years. The drug has already received several key designations from regulatory bodies, highlighting its importance for this rare condition.